Introduction {#Sec1}
============

In December 2019, the novel coronavirus disease 19 (COVID-19) emerged in Wuhan, China. The virus (SARS-CoV-2) spread rapidly around the globe and was declared a pandemic in March 2020 by the World Health Organization.

The COVID-19 clinical symptoms are well-known, and the radiological lung imaging were features widely described \[[@CR1]\]. Chest CT imaging of confirmed COVID-19 infection mainly shows typical peripheral or subpleural ground-glass opacities (GGO) and ground glass with consolidation and crazy paving \[[@CR1], [@CR2]\].

Some patients may be asymptomatic at the beginning of the infection or for the entire period of the disease and may contribute to the diffusion of the virus among the population \[[@CR1]\]. Chest CT can identify signs of COVID-19 in asymptomatic subjects \[[@CR3]\]. In asymptomatic subjects, radiological abnormalities are more likely to be unilateral, multifocal, predominantly GGOs that will rapidly evolve to bilateral disease \[[@CR4]\].

Patients with cancer who are referred to a nuclear medicine department for 18F-FDG-PET/CT screening may have previously contracted COVID-19 but remain asymptomatic. Incidental findings suggestive of COVID-19 may not be infrequent in hybrid imaging of asymptomatic patients, in geographic regions with expansive spread of COVID-19 infection \[[@CR5]\].

The aim of this 18F-FDG-PET/CT case series is to compare the incidence of these incidental findings in the pre-COVID period to those in the pandemic phase and to describe various suspicious presentations with COVID-19 incidental findings in asymptomatic patients in an area of low prevalence of the virus.

Materials and methods {#Sec2}
=====================

Population {#Sec3}
----------

We retrospectively reviewed PET/CT scans performed on COVID-19 asymptomatic cancer patients for routine oncological indication in the Nantes PET Center France, from January 1, 2020, to February 21, 2020 (*n* = 867 PET/CT) and from March 16, 2020, to April 17, 2020 (*n* = 529 PET/CT).

The period from March 16, 2020, to April 17, 2020, was the beginning of the period of social containment in France, and patients were determined to be asymptomatic for COVID-19 infection following questioning and systematic facial temperature measurements before entering the Nuclear Medicine Department. The period from January 1, 2020, to February 21 is considered to be the period before defined COVID-19 epidemia in our region.

Patients younger than 18 years old and patients with concomitant known inflammatory lung diseases were excluded from our report. No suspicion of viral infection was present in the days before or at the time of the PET/CT scan in any of our patients.

PET/CT protocols {#Sec4}
----------------

Oncological 18F-FDG PET/CT were performed on patients fasted for at least 6 h, with blood glucose \< 12 mmol/L, 60 min after injection of 3 MBq/kg of 18F-FDG, with a free-breathing helical CT, using either a Biograph mCT64 or a Vision 450 PET/CT (Siemens). An additional deep breath CT scan was performed if there was any doubt about CT abnormalities.

All PET/CT were reviewed by two experienced nuclear medicine physicians specializing in thoracic imaging. In case of doubt, a review was carried out by a radiologist. The criteria used were the presence of GGOs, consolidation, crazy paving, peripheral or central distribution, number of lobes involved, and unilateral or bilateral distribution. Visual quantification of lung involvement was classified as minimal if less than 10%, moderate between 10 and 25%, and significant between 26 and 50% as recommended by the French Thoracic Imaging Society. Maximum standardized uptake value (SUVmax) measurements were reported.

Results {#Sec5}
=======

Before the outbreak of COVID-19 (Jan 2020 to Feb 2020 cohort), CT abnormalities consistent with interstitial lung disease were found in 2.2% of patients (*n* = 19). 17/19 of these lesions were 18F-FDG positive (range SUVmax from 2.23 to 12.05).

During the containment period (March 2020 to April 2020), CT interstitial anomalies were identified in 3.8% (*n* = 20) of patients. 18F-FDG avidity was observed in 18 out of 20 patients with a SUVmax ranging from 1.58 to 13.64.

A pattern of unilateral abnormality was observed in 12 patients (60%, case 1). A bilateral abnormality was observed in 8 patients (40%). Of these, 2 had minimal involvement (case 2), 4 had moderate involvement (case 3), and 2 had significant involvement (case 4). We did not observe more than 50% involvement in our cohort. Case 5 also illustrated the nonspecific crazy-paving pattern.

Case 1 {#Sec6}
------

A 63-year-old woman underwent 18F-FDG PET/CT for staging of locally advanced triple negative breast cancer. PET/CT showed a FDG-avid left breast mass and positive axillary lymph nodes. Additionally, focal GGOs with partial consolidation, ill-defined, and subpleural distribution in the middle lobe with FDG uptake were visualized (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Maximum intensity projection (MIP) (**a**) showing hypermetabolic left breast mass and axillary lymph nodes (red circle). Subsequent axial CT (**b**), PET (**c**), and fused PET/CT images (**d**) showing focal GGOs with partial consolidation in the middle lobe, with moderate 18F-FDG uptake (orange arrows). SUVmax 3.06

Case 2 {#Sec7}
------

A 57-year-old woman diagnosed with lymph node metastatic breast cancer underwent an 18F-FDG PET/CT for postoperative staging. PET/CT showed GGOs with increased FDG uptake in the lower right lobe and subpleural GGOs in the upper left lobe without FDG uptake. Bilateral lung opacities were less than 10% of the lung parenchyma (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Subsequent axial CT (**a**, **d**), PET (**b**, **e**), and fused PET/CT images (**c**, **f**) PET/CT showing GGOs with moderate 18F-FDG uptake in the lower right lobe (SUVmax 2.95) (orange arrows) and GGOs subpleural in the upper left lobe without 18F-FDG uptake (red circle)

Case 3 {#Sec8}
------

A 70-year-old man underwent 18F-FDG PET/CT for the assessment of a lung nodule. PET/CT performed 1 month after chest CT showed new GGOs and consolidation of the 5 lobes with peripheral and lower lobe predominance with FDG uptake. Bilateral lung involvement was moderate. The rapid evolution of lung opacities and no symptoms were suggestive of COVID-19 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Subsequent axial CT (**a**, **b**) and fused PET/CT images (**e**, **f**) showing ground-glass opacities in the periphery of the lungs with high 18F-FDG uptake (orange arrows). SUVmax 13.64. MIP (**c**) demonstrating moderate bilateral lung involvement. Additional deep breath CT images (**d**) allows to improve visualization of ground-glass opacities in the right lower lobe and left lower lobe in contact with a pleural effusion without 18F-FDG uptake (blue arrows). Previous CT thorax axial images (**g**) show that the pleural effusion is identical and ground-glass opacities were not present

Case 4 {#Sec9}
------

A 65-year-old woman affected by metastatic breast cancer was referred for 18F-FDG PET/CT to assess therapy response. When compared with her previous exam, PET/CT FDG showed a lower uptake in the mediastinal nodes, contrasting with the appearance of bilateral and peripheral GGOs and consolidation with FDG uptake in the 5 lobes. The appearance of these lung opacities without symptoms was strongly indicative of COVID-19 in the context of a pandemic (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Subsequent axial of previous fused PET/CT images (**a**, **b**) showing lymph node metastasis of breast cancer in the right hilum with avid 18F-FDG (red arrow). Subsequent fused PET/CT (**d**, **e**) and axial CT images (**f**, **g**) showing a decrease in 18F-FDG uptake in the right hilum and new bilateral and peripheral GGOs and consolidation with moderate 18F-FDG uptake (orange arrows). SUVmax 4.53

Case 5 {#Sec10}
------

A 63-year-old man was referred for 18F-FDG PET/CT for staging of left lung adenocarcinoma. PET/CT confirmed increased FDG uptake of the lung mass and showed minimal FDG uptake of diffuse GGO with superimposed interlobular septal thickening and intralobular lines mostly in the left upper lobe of the lung. This crazy-paving pattern offers a wide range of differential diagnoses, in this context bronchioloalveolar carcinoma or intra-alveolar hemorrhage, and is not specific of COVID-19 infection (Fig. [5](#Fig5){ref-type="fig"}).Fig. 518F-FDG PET/CT (axial CT-upper row, axial PET- middle row, axial fused PET/CT-lower row) showing increased FDG uptake of a lung mass (orange arrow) with minimal 18F-FDG uptake of GGO, interlobular septal thickening and intralobular lines mostly in the left upper lobe of the lung (blue arrow). SUVmax 15.75

Discussion {#Sec11}
==========

We showed an increase of 1.6% in lung opacities suspected of COVID-19 in asymptomatic patients during the containment period. Although this appears to be a small increase, it is of the same order as the rate of circulation of SARS-CoV-2 in our region (the cumulative rate of patients tested positive for COVID-19 in our department was 59.1 per 100,000 inhabitants on April 17, 2020, according to Agence Régionale de Santé Pays de Loire). This population must be considered a group of risk, due to several reasons in particular because of the immunosuppression that may be induced by disease or ongoing therapies.

The typical pattern of CT imaging features for COVID-19 is well-known with GGOs and/or consolidation, most often bilateral, rather peripheral and with lower lobe involvement \[[@CR6]\]. Here, we report various forms of suspected presentations of COVID-19 in asymptomatic patients. Unilateral involvement is not uncommon \[[@CR3], [@CR4]\], up to 60% in subclinical patients \[[@CR4]\]. Our findings concur, but false positive cases are possible. In addition, the extent of CT abnormalities is usually minimal to moderate in these patients, but significant involvement, more than 25% of the lung parenchyma, can be observed even without symptoms.

The CT parameters of PET/CT are not as efficient as those of diagnostic chest CT scans. However, in case of doubt, we have made an additional deep breath CT in order to limit respiratory artifacts.

In our study, the majority of patients with suspected COVID were FDG-positive \[[@CR5], [@CR7]\]. However, FDG-negative abnormalities such as curvilinear subpleural opacities remain suspicious for COVID-19.

The main limitation of our study is the lack of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) confirmation of FDG PET/CT cases, because at that time of the outbreak, the regional health and government authorities in our country do not recommend RT-PCR tests in the absence of symptoms. In our series, only 4 patients had an RT-PCR test after PET/CT. Two patients had significant lung involvement. For one, nasopharyngeal RT-PCR was positive. For the other, RT-PCR was negative. This is a patient being treated with ribociclib-fulvestrant for breast cancer. Drug-induced lung disease with this treatment is very rare. Ribociclib can induce dyspnea and cough, but this patient was not symptomatic. Due to the context, clinical presentation, and sensitivity of RT-PCR, a negative test does not eliminate the diagnosis of COVID-19. The two others patients were addressed for staging of cancer, and they had minimal and moderate unilateral involvement. Nasopharyngeal RT-PCR tests were negative for both, and one had a PCR test bronchoalveolar lavage fluid because of development of respiratory symptoms a few days after PET/CT which was also negative for COVID-19. For these patients, clinical evolution was favorable.

In the other patients, in the absence of RT-PCR tests, given the overlap of CT and 18F-FDG PET/CT imaging features between COVID-19 and another interstitial lung disease like other viral pneumonia or cancer therapy-induced lung disease, false-positive cases of COVID-19 can be identified. Aware that imaging is not recommended as a screening tool for COVID-19 and more specifically FDG PET/CT. However, in the event of findings suggestive of COVID-19, measures must be taken to limit the spread. For all patient with suspicion of COVID-19, we informed them and advised to respect social distancing measures and barrier gestures. We have also informed the patient's medical referent in order to set up surveillance in these patients considered a group of risk.

Because of the lack of consensus in France for the treatment of asymptomatic patients, no specific treatment has been received.

Another limitation is the comparison with a control group considered to be free from risk of COVID-19 infection. In some parts of Europe in that period, the viral infection was already present. This could constitute a bias.

When available, serological tests could be proposed to refine and retrospectively validate the COVID-19 lung infection pattern; but they are not currently fully validated in France.

Conclusion {#Sec12}
==========

Nuclear medicine physicians should familiarize themselves with the pattern of interstitial anomalies on lung CT images. Indeed, identifying asymptomatic infected patients is important, so that they can be treated efficiently and ensure the safety of caregivers and the public.
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